cholangiocarcinoma/obésité

Le lien est enregistré dans le presse-papiers

Choisissez le type de tri

Page 1 de 70 résultats

Intrahepatic cholangiocarcinoma in an obese patient qualified for laparoscopic bariatric surgery - a case study.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Intrahepatic cholangiocarcinoma is a rare type of biliary tract malignancy, seldom found resectable at diagnosis, the 5-year survival rate depending on the possibility of complete surgical excision. In most cases it is only accidentally found in the early stage. The report presents a case of a

Synchronous Laryngeal Squamous Cell Carcinoma and Intrahepatic Cholangiocarcinoma Present in an Obese Male with Poor Prognosis.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Concurrent laryngeal squamous cell carcinoma and intrahepatic cholangiocarcinoma is rare and no prior report has been found through a PubMed search. Here we report such a case of a 51-year old obese male presenting with hoarseness and trouble swallowing for 2 to 3 months. Imaging findings of

Obesity and the risk of cholangiocarcinoma: a meta-analysis.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

A number of studies have shown that obesity is implicated in the susceptibility to several cancers. However, the association between obesity and cholangiocarcinoma remains unclear. This meta-analysis aimed to quantitatively assess the association between overweight or obesity and the incidence of

Overweight, obesity and the risk of gallbladder and extrahepatic bile duct cancers: A meta-analysis of observational studies.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Epidemiological studies have repeatedly investigated the association between excess body weight and the risk of biliary tract cancer with inconsistent results. The objective of this study was to quantitatively assess the associations between overweight and obesity and the risk of biliary tract

Downregulation of Fat Mass and Obesity Associated (FTO) Promotes the Progression of Intrahepatic Cholangiocarcinoma.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Intrahepatic cholangiocarcinoma (ICC) ranks as the second most malignant type of primary liver cancer with a high degree of incidence and a very poor prognosis. Fat mass and obesity-associated protein (FTO) functions as an eraser of the RNA m⁶A modification, but its roles in ICC

Predictors of unresectability after portal vein embolization for centrally located cholangiocarcinoma.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

The curative treatment of perihilar cholangiocarcinomas and centrally located intrahepatic cholangiocarcinomas often requires major hepatectomy preceded by portal vein embolization. This strategy, however, is associated with a high rate of dropouts before operation or failure of

Metabolic syndrome and the risk of cholangiocarcinoma: a hospital-based case-control study in China.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

UNASSIGNED Metabolic syndrome is regarded as a risk factor for hepatocellular carcinoma. However, no research has been conducted to investigate the association between metabolic syndrome and cholangiocarcinoma (CCA), especially in the Chinese population. Herein, a hospital-based case-control study

Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-X(L) and Mcl-1 expressing human cholangiocarcinoma cells.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

BACKGROUND Cholangiocarcinoma cells express high levels of the antiapoptotic proteins Bcl-X(L) and Mcl-1 and are markedly chemo- and radioresistant. Mitochondria have emerged as central players in apoptosis. Antiapoptotic members of the Bcl-2 protein family localise to the outer mitochondrial

A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Peroxisome proliferator-activated receptor-delta (PPARdelta) is a nuclear receptor implicated in lipid oxidation and the pathogenesis of obesity and diabetes. This study was designed to examine the potential effect of PPARdelta on human cholangiocarcinoma cell growth and its mechanism of actions.

Is cholangiocarcinoma another complication of insulin resistance: a report of three cases.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

BACKGROUND Cholangiocarcinoma is the second most common primary liver cancer, and the number of cases of intrahepatic cholangiocarcinoma (ICC) have been steadily increasing worldwide. Although the reasons for this surge are unknown, insulin resistance (IR) could be a risk factor, similar to what has

Insights into the origin of intrahepatic cholangiocarcinoma from mouse models.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Cholangiocarcinoma is a malignant cancer of the bile ducts that can be anatomically classified as intrahepatic (ICC), perihilar (PCC), or extrahepatic (ECC). ICC is the second most common primary liver cancer (PLC) (1) and is beset by late diagnoses and poor prognoses, with the overall 5-year

Avoidable cancers in the Nordic countries. Diet, obesity and low physical activity.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

In the early 1980s, Doll and Peto estimated that about 35% of all deaths from cancer in the United States were attributable to dietary factors, with a margin of uncertainty ranging from 10 to 70%. Since then, several dietary factors, e.g. fat and meat, have been suggested to increase the risk for

Incidental Intra-Hepatic Cholangiocarcinoma and Hepatocholangiocarcinoma in Liver Transplantation: A Single-Center Experience.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

BACKGROUND Cholangiocarcinoma (CCA) is an aggressive malignancy of the biliary tract that is a challenging issue for the medical community, with increasing incidence. Risk factors for CCA are similar to those known for hepatocellular carcinoma (HCC), such as cirrhosis, chronic hepatitis B and C,

Leptin enhances cholangiocarcinoma cell growth.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Cholangiocarcinoma is a strongly aggressive malignancy with a very poor prognosis. Effective therapeutic strategies are lacking because molecular mechanisms regulating cholangiocarcinoma cell growth are unknown. Furthermore, experimental in vivo animal models useful to study the pathophysiologic

Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO).

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

The incidence of Cholangiocellular carcinoma (CCA) is increasing, due to a sharp increase of the intra-hepatic form. Evidence-ascertained risk factors for CCA are primary sclerosing cholangitis, Opistorchis viverrini infection, Caroli disease, congenital choledocal cist, Vater ampulla adenoma, bile

Rejoignez notre
page facebook

Herbal & Natural Medicine

La base de données d'herbes médicinales la plus complète soutenue par la science

Fonctionne en 55 langues
Cures à base de plantes soutenues par la science
Reconnaissance des herbes par image
Carte GPS interactive - étiquetez les herbes sur place (à venir)
Lisez les publications scientifiques liées à votre recherche
Rechercher les herbes médicinales par leurs effets
Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets

Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées